Abeona Therapeutics INC Form 4 insider transactions

ABEONA THERAPEUTICS Director Michael Amoroso acquired 37,313 shares of common stock, increasing his beneficial ownership to 217,779 shares.

ABEONA THERAPEUTICS Director Faith L. Charles acquired 37,313 shares of common stock, increasing her beneficial ownership to 176,407 shares.

ABEONA THERAPEUTICS Director Mark Alvino acquired 37,313 shares of common stock, increasing his beneficial ownership to 86,065 shares, with vesting set for January 26, 2027.

Abeona Therapeutics Director Leila Alland received a grant of 37,313 shares of common stock, increasing her beneficial ownership.

Abeona Therapeutics' Chief Commercial Officer, Madhav Vasanthavada, reported the acquisition of restricted stock and a subsequent sale to cover tax obligations.

Abeona Therapeutics CFO Joseph Vazzano sold 18,666 shares of common stock at a weighted average price of $5.3309 to cover tax obligations from restricted stock vesting.

Abeona Therapeutics CEO Vishwas Seshadri reported the sale of 69,832 common shares on January 22, 2026, to cover tax liabilities from restricted stock vesting.

ABEONA Therapeutics' SVP, Chief Legal Officer, Brendan M. O'Malley, sold 13,578 shares of common stock on January 22, 2026, to cover tax obligations from restricted stock vesting.

Abeona Therapeutics Director Mark Alvino reported the sale of 13,500 shares of common stock at a weighted average price of $5.2277.

Brendan M. O'Malley, SVP and Chief Legal Officer of Abeona Therapeutics, acquired 113,949 shares of common stock through a grant.

Joseph Vazzano, Chief Financial Officer of Abeona Therapeutics Inc., was granted 133,595 shares of common stock, which will vest over a three-year period.

ABEONA THERAPEUTICS INC. CEO Vishwas Seshadri reported the acquisition of 365,422 shares of common stock, which will vest over the next three years.

ABEONA THERAPEUTICS INC. CEO Vishwas Seshadri sold 25,000 shares of common stock for approximately $5.31 per share as part of a pre-arranged trading plan.

Mark Alvino, a Director at Abeona Therapeutics Inc., reported the sale of 15,000 shares of common stock at a weighted average price of $4.7445 pursuant to a Rule 10b5-1 plan.

ABEONA THERAPEUTICS CEO Vishwas Seshadri sold 249 shares of common stock on October 16, 2025, to cover tax obligations related to restricted stock vesting.

Brendan M. O'Malley, SVP and Chief Legal Officer of Abeona Therapeutics Inc., sold 9,366 shares of common stock to cover tax obligations.

Abeona Therapeutics CEO Vishwas Seshadri sold 44,274 shares of common stock across two transactions in late September 2025, primarily for tax obligations and a pre-arranged trading plan.

Joseph Vazzano, Chief Financial Officer of Abeona Therapeutics Inc., sold 9,035 shares of common stock to cover tax obligations from restricted stock vesting.

Brendan M. O'Malley, SVP and Chief Legal Officer of Abeona Therapeutics, sold 688 shares of common stock to cover tax obligations related to restricted stock vesting.

A director at Abeona Therapeutics Inc. sold 4,718 shares of common stock to cover tax obligations related to restricted stock awards.

Abeona Therapeutics' Chief Financial Officer, Joseph Vazzano, sold 15,000 shares of common stock for approximately $7.36 per share in a pre-scheduled transaction.

Abeona Therapeutics' Chief Financial Officer, Joseph Walter Vazzano, sold 1,502 shares of common stock to cover tax obligations related to restricted stock awards.

ABEONA THERAPEUTICS Director Christine Berni Silverstein sold 13,093 shares of common stock at a weighted average price of $5.8557 to cover tax obligations from restricted stock award vesting.

Abeona Therapeutics Inc. CEO Vishwas Seshadri sold 69,420 shares of common stock on July 9, 2025, to cover tax obligations related to restricted stock awards.

Abeona Therapeutics' Chief Financial Officer, Joseph Vazzano, sold 25,411 shares of common stock to cover tax obligations related to restricted stock awards.

Donald A. Wuchterl, a director at Abeona Therapeutics Inc., sold 5,176 shares of common stock for a weighted average price of $5.8244 per share, as part of a pre-established Rule 10b5-1 trading plan.

ABEONA THERAPEUTICS Director Faith L. Charles reported the sale of 10,738 shares of common stock on July 9, 2025, at a weighted average price of $5.8557 per share, primarily to cover tax obligations from restricted stock award vesting.

Brendan M. O'Malley, SVP and Chief Legal Officer of Abeona Therapeutics Inc., sold 17,428 shares of common stock on July 9, 2025, to cover tax obligations related to restricted stock vesting.

ABEONA THERAPEUTICS Director Mark Alvino sold 13,093 shares of common stock on July 9, 2025, at a weighted average price of $5.8557 to cover tax obligations from restricted stock award vesting.

Abeona Therapeutics Inc.'s Chief Financial Officer, Joseph Vazzano, was granted 13,333 shares of common stock as restricted stock units, vesting over three years.